文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

疑似感染入院时继续与停用家庭β受体阻滞剂:目标试验模拟

Continuing vs. Withholding Home Beta-Blockers at Admission for Suspected Infection: A Target Trial Emulation.
PubMed 文献 · Crit Care Med · 2026-06-09
一句话结论疑似感染入院患者继续口服家庭β受体阻滞剂与90天全因死亡率降低相关(HR 0.77),但需对照实验研究验证。

该回顾性队列研究采用目标试验模拟框架,在美国中西部一家大型学术三级医疗急诊科纳入4635例入院前服用β受体阻滞剂的疑似感染成人患者,比较入院48小时内继续口服β受体阻滞剂与未继续者的结局。继续用药与90天全因死亡率降低相关(HR 0.77;95%CI 0.61-0.98;p=0.03),并缩短住院时间(IRR 0.39;95%CI 0.38-0.41;p<0.001),但与院内死亡率无显著关联(OR 0.60;95%CI 0.30-1.20;p=0.15)。作者认为需开展对照实验研究评估疑似脓毒症住院患者继续慢性β受体阻滞剂的作用。

要点

  • 疑似感染入院患者继续口服β受体阻滞剂与90天全因死亡率降低相关(HR 0.77;95%CI 0.61-0.98;p=0.03)。
  • 继续β受体阻滞剂与住院时间缩短相关(IRR 0.39;95%CI 0.38-0.41;p<0.001)。
  • 继续β受体阻滞剂与院内死亡率无显著关联(OR 0.60;95%CI 0.30-1.20;p=0.15)。
  • 该研究排除休克、心率<40或>120、需静脉β受体阻滞剂或钙通道阻滞剂的患者,结果不能外推至这些人群。
  • 作者认为需开展对照实验研究评估疑似脓毒症住院患者继续慢性β受体阻滞剂的作用。

适用人群与场景

  • 年龄≥18岁、入院前服用β受体阻滞剂、因疑似感染住院的患者;疑似感染定义为开具血培养和广谱抗生素医嘱。
  • 排除休克、心率<40或>120、临床医生决定需静脉β受体阻滞剂或钙通道阻滞剂的患者。

诊断标准与关键阈值

  • 疑似感染定义:开具血培养和广谱抗生素医嘱。

处置流程与药物剂量

  • 继续组:入院48小时内继续口服β受体阻滞剂;对照组:未继续口服β受体阻滞剂。

研究设计与关键结果

  • 研究类型:回顾性队列研究,采用目标试验模拟框架;单家美国中西部大型学术三级医疗急诊科;4635例 eligible 患者,1172例(25.3%)接受口服β受体阻滞剂,3463例(74.7%)未接受。
  • 主要终点:继续β受体阻滞剂与90天全因死亡率降低相关(HR 0.77;95%CI 0.61-0.98;p=0.03),采用Cox回归并以逆概率治疗加权校正基线差异(性别、种族、民族、年龄、体重指数、不复苏医嘱、合并症、急性病情严重程度)。
  • 关键次要终点:继续β受体阻滞剂与住院时间缩短相关(IRR 0.39;95%CI 0.38-0.41;p<0.001);与院内死亡率无显著关联(OR 0.60;95%CI 0.30-1.20;p=0.15)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(目标试验模拟框架)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在广泛疑似感染住院患者中继续慢性β受体阻滞剂与临床结局改善相关;作者支持需开展对照实验研究评估疑似脓毒症住院患者继续慢性β受体阻滞剂的作用。
  • 研究结果不适用于休克、心率<40或>120、或需静脉β受体阻滞剂/钙通道阻滞剂的患者(为排除人群)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Beta-blockers are commonly prescribed for chronic cardiovascular diseases. Despite potential benefits in septic shock, beta-blockers are often held at hospital admission for patients with suspected infection and possible sepsis. We compared the effects of chronic beta-blocker continuation vs. discontinuation on 90-day all-cause mortality among patients admitted from the emergency department with suspected infection.

DESIGN: Retrospective cohort study using the target trial emulation framework. We used Cox regression to compare 90-day mortality between treatment groups, with inverse probability of treatment weights to account for baseline differences in sex, race, ethnicity, age, body mass index, presence of a "do not resuscitate" order, comorbidities, and acute illness severity.

SETTING: A single large, academic, tertiary care emergency department in the Midwest United States.

PATIENTS: Patients 18 years or older on beta-blockers prior to admission hospitalized for suspected infection (defined by orders for blood cultures and broad-spectrum antibiotics). Patients with shock, heart rates less than 40 or greater than 120, or who required an IV beta- or calcium channel blocker at a clinician's discretion were excluded.

INTERVENTIONS: Continuation of oral beta-blockers within 48 hours of admission vs. no continuation.

MEASUREMENTS AND MAIN RESULTS: Of 4635 eligible patients, 1172 (25.3%) received an oral beta-blocker, whereas 3463 (74.7%) did not receive an oral beta-blocker. Beta-blocker continuation was associated with a reduced risk of all-cause mortality within 90 days of hospital admission (hazard ratio 0.77; 95% CI, 0.61-0.98; p = 0.03) and shorter hospital stay (incidence rate ratio 0.39; 95% CI, 0.38-0.41; p < 0.001). There was no significant association between beta-blocker continuation and in-hospital mortality (odds ratio 0.60; 95% CI, 0.30-1.20; p = 0.15).

CONCLUSIONS: Continuation of chronic beta-blockers in a broad population of patients admitted with suspected infection was associated with improved clinical outcomes. Our findings support the need for controlled experimental studies evaluating the role of chronic beta-blocker continuation among patients hospitalized with possible sepsis.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Christian-Miller N, Lee KT, Pashun R, et al. Continuing vs. Withholding Home Beta-Blockers at Admission for Suspected Infection: A Target Trial Emulation. Crit Care Med. 2026. PMID: 42262489. doi:10.1097/CCM.0000000000007229

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。